Latest Breaking News On - இடைக்கால பகுப்பாய்வு - Page 11 : comparemela.com
Les contaminations en baisse de 61 aux États-Unis
lessentiel.lu - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lessentiel.lu Daily Mail and Mail on Sunday newspapers.
Des réponses avec l OMS à Wuhan? «Peu probable»
lessentiel.lu - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lessentiel.lu Daily Mail and Mail on Sunday newspapers.
Le variant brésilien est arrivé en France
lessentiel.lu - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lessentiel.lu Daily Mail and Mail on Sunday newspapers.
Biophytis Announces the Start of Patient Recruitment in Brazil and the USA for Part 2 of the Phase 2-3 COVA Trial (“COVA Study”)
Patient recruitment in Part 2 of the COVA Study will begin in most clinical centers in Brazil and the United States
Interim Analysis of Part 1 is expected in Q1 2021
Results from the full study (Part 1 and Part 2) are expected in Q2 2021
/EIN News/ PARIS and CAMBRIDGE, Mass., Feb. 03, 2021 (GLOBE NEWSWIRE) Biophytis SA (Euronext Growth Paris: ALBPS), a clinical-stage biotechnology company focused on the development of therapeutics that slow the degenerative processes associated with aging and improve functional outcomes for patients suffering from age-related diseases, including severe respiratory failure in patients suffering from COVID-19, today announces that patient recruitment at most clinical centers in Brazil and the United States will begin for Part 2 of its COVA Study assessing Sarconeos (BIO101) as a potential treatment for acute res
Published: Feb 03, 2021
Patient recruitment in Part 2 of the COVA Study will begin in most clinical centers in Brazil and the United States
Interim Analysis of Part 1 is expected in Q1 2021
Results from the full study (Part 1 and Part 2) are expected in Q2 2021
PARIS and CAMBRIDGE, Mass., Feb. 03, 2021 (GLOBE NEWSWIRE)
Biophytis SA (Euronext Growth Paris: ALBPS), a clinical-stage biotechnology company focused on the development of therapeutics that slow the degenerative processes associated with aging and improve functional outcomes for patients suffering from age-related diseases, including severe respiratory failure in patients suffering from COVID-19, today announces that patient recruitment at most clinical centers in Brazil and the United States will begin for Part 2 of its COVA Study assessing Sarconeos (BIO101) as a potential treatment for acute respiratory failure associated with COVID-19.